Skip to Main Content

More and more children are developing food allergies — and biotech companies are springing up to take advantage of the demand for treatments.

First on the scene, when parents and, eventually, allergists began to notice the increase in children’s food allergies, was Aimmune Therapeutics. The company was founded to prevent severe allergic reactions from happening, rather than react to them with epinephrine injections. In January 2020, just under a decade after its start, Aimmune’s oral immunotherapy became the first Food and Drug Administration-approved peanut allergy treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment